IXICO PLC (AIM: IXI) — Investment Research Note
Executive summary
IXICO is a UK-listed neuroscience imaging Contract Research Organisation (iCRO) that uses its proprietary AI-driven IXI™ platform to analyse brain scans for biopharma clients running neurological drug trials (Alzheimer's, Parkinson's, Huntington's). The five-year trajectory shows a business that has stabilised after twin shocks (large HD trial cancellations in 2021 and 2022 wiped revenue/order book) and returned to growth (+13% FY25, +23% H1 26), with management now pivoting via a "TechBio" strategy to platform-license its IXI™ technology to larger CROs (Medidata partnership signed March 2026). The single most important valuation point today is that the post-money market cap of £18.9m vs ~£11m net cash leaves an implied enterprise value of just ~£8m for a £6.5m-revenue, 53%-gross-margin specialist platform business with a £18.1m contracted order book.
Fair value estimate
Methodology: Sum-of-parts using EV/Sales multiple on the core iCRO business plus net cash. Given persistent EBITDA losses, DCF is not robust; given micro-cap status and a stated management "TechBio" thesis (which they argue should attract 4–7x revenue vs. 1–3x for CROs), a revenue-multiple frame is appropriate.
Key assumptions:
- Net cash post-raise: ~£11m (£1.7m at 31 Mar 26 + £9.4m net April 2026 raise, 2026-05-19 H1)
- FY26E revenue ~£7.5m (15% guided growth on £6.5m FY25, 2026-05-19 H1)
- FY27E revenue ~£8.5m (continued growth, conservative)
- Conservative case: 1.5x FY27E revenue (typical CRO multiple low end)
- Central case: 2.5x FY27E revenue (justified by scientific niche, AI platform, 53%+ gross margin trajectory)
- Bull case: 4.0x FY27E revenue (if TechBio licensing model gains traction)
Fair value range per share (218m shares):
- Low: (1.5 × £8.5m) + £11m = £23.75m → ~10.9p
- Mid: (2.5 × £8.5m) + £11m = £32.25m → ~14.8p
- High: (4.0 × £8.5m) + £11m = £45m → ~20.6p
Implied market cap range: £23.75m – £45m Current market cap: £18.9m Upside to mid-point: +71% (vs. 8.65p current price to 14.8p mid) Upside range: +26% (low) to +138% (bull)
Sector context
- Sector: Health Care (Health Care Services / Pharma Services sub-sector). Specifically a niche neuroimaging iCRO.
- Quality/growth/leverage profile: Below typical large-cap CRO peers in scale and profitability (loss-making, sub-scale), in-line on growth (mid-teens %), and ahead on balance sheet (net cash, no debt) following the April 2026 raise.
- Listed peers: Difficult to name pure neuroimaging CROs publicly. Closest comparables: Clario (private, ThermoFisher acquisition reference, 2026-03-31 placing circular); Perspectum (private); broader CRO peers ICON plc, IQVIA; in AI-medical-imaging: Brainomix (AIM:BOX) — also UK small-cap specialist.
Investment thesis
- Genuine AI in medical imaging with paying customers — IXI™ is not press-release AI: hundreds of thousands of scans processed, 53% gross margin, validated platform now in v10. The Medidata commercial collaboration (used in 80% of FDA novel approvals) is real third-party validation 2026-05-19 H1.
- Operating leverage inflection visible — Revenue +23% YoY drove gross margin from 49.6% to 53.2% in H1 26 with EBITDA loss narrowing from £0.7m to £0.5m; the cost base is largely fixed (scientists, platform), so incremental revenue should drop disproportionately to profit. Management guidance to break-even at ~£8m revenue 2024-10-08 placing implies near-term inflection plausible.
- Valuation distress vs. cash + order book — At 8.65p, market cap £18.9m is barely above ~£11m net cash, implying ~£8m EV for a business with £18.1m contracted order book covering 95% of FY26 expectations 2026-05-19 H1. The new placing at 8p (premium to prior close) was oversubscribed and backed by Octopus and Gresham House 2026-03-31 placing.
Key risks
- Persistent dilution and equity funding dependence — Two capital raises in 18 months (Oct 2024 £3.7m net; April 2026 £9.4m net), share count up from 48m to 218m — a 4.5x expansion. Continued losses + investment in TechBio strategy may require further raises 2026-03-31 placing; 2024-10-08 placing.
- Customer concentration and trial cancellation history — Track record includes two major client trial cessations (March 2021, January 2022) that materially descoped the order book. Pharma R&D cycles and biotech funding remain unpredictable 2024-05-21 H1; 2022-05-24 H1.
- TechBio strategy execution risk — The £10m raise is explicitly for an unproven pivot (platform licensing, FDA SaMD approval). Management's premise that this attracts 4-7x revenue multiples is speculative; if licensing revenue doesn't materialise, the business remains a sub-scale iCRO at 1-3x revenue 2026-03-31 placing.
Operating leverage
The H1 26 results illustrate the leverage in stark form: revenue +23% (£3.9m vs £3.2m) drove gross profit +31% (£2.1m vs £1.6m) while the operating expense base grew only ~19% (£3.3m vs £2.8m). Gross margin moved 360bps to 53.2%; management explicitly notes "the relatively fixed nature of IXICO's costs of delivery" 2026-05-19 H1. With ~80 employees (~50%+ of cost base) and a fixed-cost cloud platform, an additional 10-20% revenue beat above the ~£7.5m FY26 trajectory could close most of the £1.3m FY25 EBITDA loss, given that incremental gross profit would land at 55-60%+ on largely flat operating expense. The 2024 placing circular flagged ~£8m revenue as the break-even threshold 2024-10-08 placing. Above that point, contribution margin compounding suggests EBIT could exit a £10m revenue run-rate with mid-teens EBITDA margins — a multi-bagger of profit per pound of incremental revenue.
Value-trap signals
- Repeated rescue capital raises at progressively lower share prices — Oct 2024 at 9.5p; April 2026 at 8p — diluted base ~4.5x in 18 months, suggests structural inability to self-fund growth.
- Loss-making for the entire period covered by these filings (FY22 was the only EBITDA-positive year at £1.5m, since reversed).
- Client/trial concentration risk has materialised twice in the period (HD trial cessations 2021 and 2022) — not idiosyncratic, structural to small CRO.
- Going-concern language softening but persistent investment phase — even with £11m cash, business plan calls for cash burn into FY27 to fund TechBio.
Earnings vs. expectations
Across the period, performance vs. guidance has been mixed but improving recently. The March 2024 trading update was a clear miss/profit warning (FY24 revenue cut to £5.2–5.9m from prior expectations) due to contract delays 2024-03-13. The August 2024 update upgraded to £5.5–5.9m, and FY24 delivered £5.8m — in line with revised guidance 2024-08-14. FY25 trading updates progressively beat expectations (July 2025 raised to ≥£6.3m; October 2025 actual £6.5m, "exceeded market expectations") 2025-07-17; 2025-10-16. H1 26 came in 23% YoY, in line with the April pre-close update 2026-04-21; 2026-05-19. Pattern: a profit warning in early 2024 followed by a consistent run of in-line/beat results under new CEO Bram Goorden — more beats than misses recently, but the longer record includes the 2021/2022 trial-cessation shocks.
Conviction
3/5 — moderate.
Anchors: (1) clean and timely AIM disclosure with detailed order book and cash bridges; (2) reasonable visibility from £18.1m contracted order book (95% of FY26 mkt expectation); (3) multiple converging valuation approaches (EV/revenue, sum-of-parts, cash floor) all suggest the stock is undervalued at the current price.
Limits: (1) loss-making business — DCF is not robust and any fair value rests on a revenue-multiple assumption that ranges from 1.5x to 4x; (2) the TechBio licensing pivot is genuinely binary — execution success could double the multiple, failure leaves them as a sub-scale CRO trading on cash + 1.5x revenue, which is barely above today's price.
Driver scoring summary
The company merits a medium AI score: it is a genuine AI-in-medical-imaging business with paying biopharma customers, but it is itself spending heavily on AI platform development and the value-capture from "agentic AI" diffusion doesn't obviously accrue to a sub-scale specialist CRO. High operating leverage given fixed cost base and software platform. The valuation is genuinely discounted vs. the strategy. Downside is moderated by ~£11m net cash but the loss profile and dilution history are real fragilities.
Overall score: 480 — partial fit. Strong on operating leverage and valuation, moderate on AI alignment, weak on quality/dilution history.